Supplementary Table 3. Sensitivity Analysis: 6-, 12-, 18-, and 24-Month Persistence of the Index Biologic in Patients with Crohn's Disease or Ulcerative Colitis Who Initiated Biologic Treatment during or after Year 2020

Index treatment	6 mo persistence with ≥ 6 mo continuous observation		12 mo persistence with ≥ 12 mo continuous observation		18 mo persistence with ≥ 18 mo continuous observation		24 mo persistence with ≥ 24 mo continuous observation	
	No. (%)	Total	No. (%)	Total	No. (%)	Total	No. (%)	Total
Crohn's disease								
Adalimumab	100 (90.1)	111	87 (84.5)	103	55 (80.9)	68	29 (70.7)	41
Infliximab	105 (98.1)	107	84 (88.4)	95	50 (84.7)	59	25 (75.8)	33
Vedolizumab	21 (77.8)	27	16 (59.3)	27	8 (50.0)	16	3 (30.0)	10
Ustekinumab	95 (93.1)	102	81 (89.0)	91	53 (88.3)	60	28 (75.7)	37
Total	321 (92.5)	347	268 (84.8)	316	166 (81.8)	203	85 (70.2)	121
Ulcerative colitis								
Adalimumab	82 (67.8)	121	62 (54.4)	114	38 (47.5)	80	15 (45.5)	33
Infliximab	129 (70.9)	182	101 (59.4)	170	57 (52.8)	108	23 (40.4)	57
Golimumab	54 (73.0)	74	37 (56.1)	66	25 (54.3)	46	15 (48.4)	31
Vedolizumab	164 (81.6)	201	118 (67.4)	175	65 (60.7)	107	27 (56.3)	48
Ustekinumab	97 (95.1)	102	78 (83.9)	93	39 (81.3)	48	18 (78.3)	23
Tofacitinib	59 (68.6)	86	47 (61.8)	76	22 (45.8)	48	10 (34.5)	29
Total	585 (76.4)	766	443 (63.8)	694	246 (56.3)	437	108 (48.9)	221